

Withdrawal of domestic application for the additional “chemotherapy-induced anemia” indication for NESP

Tokyo, Japan, January 31, 2012 ---Kyowa Hakko Kirin Co., Ltd (“Kyowa Hakko Kirin”) has withdrawn its domestic application for the additional “chemotherapy-induced anemia” indication for long-acting erythropoiesis stimulator NESP (generic name: darbepoetin alfa (genetic recombination)).

Kyowa Hakko Kirin submitted an application for approval of said indication to the Ministry of Health, Labour and Welfare in November 2008. Subsequently, the Pharmaceutical and Medical Devices Agency expressed the view that new data was required concerning the application package Kyowa Hakko Kirin had submitted. As a result, Kyowa Hakko Kirin has decided to withdraw this application for approval on this occasion.

Kyowa Hakko Kirin is continuing examination of drug development based on the domestic and international circumstances surrounding this drug.

Kyowa Hakko Kirin will be a Japan-based Global Specialty Pharmaceutical Company contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by state-of-the art antibody technologies mainly in the core therapeutic areas of oncology, nephrology and immunology.